ドライアイ感染症や目の炎症の蔓延と、無添加製品への志向の高まりが市場の発展を推進しています。特に中等度または重度のドライアイに対する眼障害などの添加物の結果から推測できる、無添加人工涙液への関心の高まりが人工涙液市場を牽引しています。さらに、重要な市場参加者による商品の発送数の増加によって、商品の分離が拡大し、その結果、市場の成長が促進されています。たとえば、2022年1月にアルコン（スイス）は、完全無添加オイル目薬Systaneを欧州市場に送り出しました。同様に、2019年10月に、Allergan, Inc. (米国AbbVieの子会社) は、Revive ポートフォリオの拡張である Invigorate Relieva グリース点眼薬を発売しました。製品にはRevive Relieva PF (無添加) マルチドーズが含まれていました。
さらに、無添加アイテムの発送拡大も人工涙液市場を牽引しています。また、汚染を未然に防ぐ無添加点眼薬の同梱計画や搬送システムの推進も人工涙液市場をさらに牽引しています。したがって、無添加アイテムへの志向の高まりが市場の拡大を推進しています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF DRY EYE DISEASE AND EYE INFLAMMATION
4.2.2 RISING PREFERENCE FOR PRESERVATIVE-FREE PRODUCTS
4.3 RESTRAINTS
4.3.1 SIDE-EFFECTS AND ALLERGIC REACTIONS
4.4 OPPORTUNITIES
4.4.1 ADVANCEMENT IN DIAGNOSTICS FOR DRY EYE DISEASE
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE ARTIFICIAL TEARS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON MANUFACTURERS
5.4 PRICING ANALYSIS
6 GLOBAL ARTIFICIAL TEARS MARKET, BY TYPE
6.1 OVERVIEW
6.2 POLYETHYLENE GLYCOL
6.3 PROPYLENE GLYCOL
6.4 CELLULOSE
6.5 GLYCERIN
6.6 OTHERS
7 GLOBAL ARTIFICIAL TEARS MARKET, BY DELIVERY MODE
7.1 OVERVIEW
7.2 EYE DROPS
7.3 OINTMENTS
7.4 SPRAYS
8 GLOBAL ARTIFICIAL TEARS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DRY EYE SYNDROME
8.3 ALLERGIES AND INFECTIONS
8.4 OTHERS
9 GLOBAL ARTIFICIAL TEARS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 DRUG STORES
9.4 RETAIL PHARMACIES
9.5 ONLINE PHARMACIES
10 GLOBAL ARTIFICIAL TEARS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.7.1 PRODUCT LAUNCH
11.7.2 COLLABORATION
11.7.3 AGREEMENT
11.7.4 ACQUISITION
11.7.5 PARTNERSHIP
11.8 MAJOR PLAYERS FINANCIAL MATRIX
11.8.1 SALES (USD BILLION), 2022
11.8.2 R&D (USD BILLION), 2022
12 COMPANY PROFILES
12.1 JOHNSON AND JOHNSON VISION CARE
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ALLERGAN PLC
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 ALCON PLC
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 BAUSCH & LOMB INCORPORATED
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 SANTEN, INC.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 URSAPHARM ARZNEIMITTEL GMBH
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 ROHTO PHARMACEUTICAL CO., LTD.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 SIMILASAN CORPORATION
12.8.1 COMPANY OVERVIEWS
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 OCUSOFT
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 NICOX
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
